Heparin and dicumarol are both useful drugs but each has its limitations and accordingly search goes on for newer drugs that lack some of these limitations. A new anticoagulant, phenylindandione produces a prothrombopenia more rapidly than dicumarol and its catabolism is equally more rapid. This, therefore, aroused interest in clinical trials utilizing this new prothrombopenic agent. Th3 drug is a light yellow, crystalline compound put up in tablet form and administered by mouth. IN 1944, Kabat, Stohlman, and Smith' described the effect of certain indandione derivatives on prothrombin levels in animals. In 1947, Soulier and Guegen2 utilized a substance called phenylindandione clinically as an anticoagulant. Jaques3 has recently stimulated interest in this latter substance by his observations that its administration to dogs resulted in the production of hypoprothrombinemia more rapidly than did the administration of dicumarol. He carried out studies to investigate the possible mechanism of its behavior, since vitamin K is without effect on the action of this drug, and to observe toxic manifestations, if any.
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This preliminary report deals with clinical trials of phenylindandione tinder controlled conditions on 20 patients. The investigation centered upon establishment of dose levels, frequency of administration, speed of action and recovery, individual responses, and possible toxicity. Sedimentation rates, platelet counts, and white blood cell differential counts were determined and liver function tests and urinalyses were performed before and after administration of the drug, in an effort to ascertain any alteration in This work was supported in part by a grant from the Charles Frosst Company, Montreal, Quebec, who also kindly supplied us with the phenylindandione (Danilone).
MATERIALS AND METHODS
Fifty-three hospitalized patients, 47 of whom had thrombotic episodes prior to administration of the drug, were the subjects of this study. Sixteen of them had acute coronary thrombosis, 17 postoperative phlebitis, 5 acute idiopathic thrombophlebitis, 1 recurrent thrombophlebitis, 1 postpartum thrombophlebitis, 1 aortic thrombosis, 1 mesenteric thrombosis, 1 subacute bacterial endocarditis, 4 pulmonary infarction, 1 popliteal aneurysm, and 1 patient suffered from cerebral thrombosis. Four patients were treated prophylactically.
1. Prothrombin concentration was determined by the one-stage modified Quick method.
2. The Westergren method was used in estimating the sedimentation rate.
Platelet counts 'were made by the Rees and
Ecker method.
4. The Lumetron calorimeter was used in performing liver function tests.
Bromsulfalein excretion was estimated by
the Rosenthal method.
DOSAGE
Initial Dose. The initial dose used was arrived at by the trial-and-error method. To Patient E.G., following determination of his prothrombin time, 50 mg. of phenylindandione were given by mouth; after four hours the prothrombin time was again determined. The prothrombin concentration was depressed only 5 per cent in that period of time; therefore 100 mg. were given at bedtime. The following morning the prothrombin concentration had dropped to 40 per cent activity and by afternoon to 25 per cent activity. The initial prothrombin concentration was 65 per cent and the drop to 25 per cent occurred in twentythree and one-half hours, after a total of 150 1195 mg. had been given. Thirty-one of the remaining patients were given 150 mg. as the total initial twelve-hour dose; some received 50 mg. in the morning and 100 mg. at night, while others received their dosage in the reverse order. This reversal of order did not seem to affect the time required to reduce the prothrombin concentration.
Patient R. H. was given 50 mg. on the first day and 100 mg. the second day; fortythree and one-half hours elapsed before the prothrombin concentration dropped from 90 per cent to 30 per cent. Patient A. G. received an initial dose of 175 mg. and twenty-nine and one-third hours later the prothrombin concentration had dropped from 100 to 25 per cent activity; forty-six hours after the initial dose, the prothrombin time was infinity. This procedure was repeated in Patient L. S. to verify the lack of control that resulted from the added dosage. She received 100 mg. in the morning and 100 mg. at night. Twenty-eight hours later the prothrombin activity had changed from 100 to 25 per cent; forty-seven hours later the prothrombin time was infinity. Therefore, it was felt that 150 mg. represented an optimum safe, adequate, dosage level, and in the case of Patient R. H. it was felt that the initial dose of 50 mg. was inadequate. One patient, L. B., required 500 mg. before his prothrombin activity was depressed from 100 to 30 per cent. We have since tried an initial dosage of 200 mg. in 16 succeeding cases and have concluded that this is more in keeping with the proper initial dosage in a man or woman weighing about 150 pounds. With this dosage the desired level was obtained within 24 to 36 hours and the prothrombin times did not go to infinity.
Frequency of Administration. As in dicumarol therapy the maintenance dose has to be gauged by the daily prothrombin time, and the level to which one cares to lower the prothrombin activity is arbitrary. Some believe that there is no therapeutic effect if a level of 10 per cent activity is not achieved, while others claim a level of 30 to 40 per cent is adequate. In this series, 30 per cent of activity was the point at which administration of the drug was stopped, and if the concentration rose above it, 50 mg. of phenylindandione were given. The average daily dosage other than the initial dose in 53 of the patients was 65 milligrams. Table 1 gives the results of phenylindandione administration in 20 patients who had been treated when this article was first prepared for publication; table 2 gives results in 33 subsequent patients. Administration varied, from case to case, from 50 to 140.6 mg. per day except in two instances where 25 mg. or less per day was the daily requirement. These 2 patients had major bowel resections. In view of the wide swings we noted in the daily prothrombin times, it was felt that the daily maintenance dose ought to be split in two in order to maintain a sustained prothrombin level. We did this in our last 15 patients and found that the prothrombin time varies much less from day to day.
RESULTS
Speed of Action and Recovery. In 18 cases the desired prothrombin level was reached in from 10 to 20 hours. In 20 cases it was reached from 20 to 28 hours later. In 7 cases it was reached in from 29 to 40 hours. In 3 cases the level was reached from 40 to 50 hours later. Patient L. B. required 500 mg. before the prothrombin activity changed from 100 per cent to 30 per cent in a period of seventy-two hours. This could be interpreted only as the same type of variation one often sees with dicumarol. In Patient L. R. it took forty-eight hours for the prothrombin activity to reach a level of 25 per cent from an initial level of 100 per cent. The initial dose of this latter patient was 150 mg., as was that of Patient L. B. In 4 cases, 500 mg. was required in order to obtain the desired effect. However, an initial dosage of 200 mg. seems to prolong the prothrombin time to clinically effective levels more rapidly.
The average time taken for the prothrombin concentration to return to its initial value was forty-eight hours, and there was little discrepancy noted in the rate of recovery.
Individual Responses and Toxicity. Jacques3 observed bleeding in only 2 dogs of his series in which prothrombin times of infinity were reached and, therefore, overdosage established. One of these dogs had received antidistemper serum at the same time the phenylindandione was administered and the other had a superficial infection. Three of our patients received doses that led to prothrombin times of infinity and one of these, Patient C. L., had hematuria which appeared only on one occasion and never recurred. He had no other signs of bleeding and cessation of the drug for fortyeight hours resulted in a return of the prothrombin activity to normal levels. Patient L. S. received 200 mg. in twelve hours and cessation of the drug in her case led to a return of the prothrombin activity to normal. The third patient, A. G., whose prothrombin activity reached infinity on an initial dose of 175 mg., did not show any signs of bleeding or have any other toxic manifestations. Patient G.D. had a slight nosebleed on the fourteenth day of administration of the drug and the prothrombin concentration on that day was 35 per cent. Up to that time he had received a total of 700 mg. of phenylindandione. Soulier and Guegen2 reported renal damage following very large doses of the drug, presumably due to deposition of the crystals in the tubules. Casts were observed in the urine of a dog receiving 50 mg. per kilogram of body weight per day on the twventy-third day of the experiment; no casts were seen in the urine of animals given smaller doses. Soulier and Guegen also observed dryness of the mouth, polydipsia, polyuria, and sometimes tachycardia after the administration of 10 and 20 mg. per kilogram of body weight per day to their patients; 2 of the patients had a brief scarlatiniform rash. We did not observe any of these toxic manifestations in our 53 patients.
We did encounter the phenomenon of what we must call resistance for lack of a better term. In one patient, H. P., we were asked to cease administering the anticoagulant prior to the onset of her menses. We allowed her prothrombin time to return to normal and one week later we attempted to reinstitute therapy but without avail. Over a period of seven days we administered 600 mg. of the drug without appreciably altering the prothrombin time. In one case, M. L., we gave 150 mg. each day for four days and the prothrombin time was prolonged only from a normal of 12 seconds to 18 seconds, which we considered clinically ineffec-tive. A third case, E. B., showed an unusual phenomenon in that we were able to prolong his prothrombin time to clinically effective levels but, despite daily increase of the dosage, the prothrombin time dropped back to normal and remained at normal levels.
Effect on Liver Function. The following determinations were made before and one week after administration of the anticoagulant: blood sugar, blood cholesterol, total protein, serum albumin, serum globulin, serum fibrinogen, hippuric acid synthesis, icteric index, van den Bergh reaction, and bromsulpthalein excretion. No significant changes could be detected in these values.
Urinalyses. These were made daily in order to check the urine for any evidence of bleeding, crystal deposition, or casts. At no time was there interference with urine output. Bloody urine was noted in Patient C. L. on the second day after phenylindandione administration when his prothrombin time was infinity. Phenylindandione and its excretion products do not appear to interfere with the reaction of Benedict's test for sugar in the urine.
Effect upon the Sedimentation Rate and Platelet and White Cell Differential Counts. In 6 of our patients the blood sedimentation rate was determined and platelet and white cell differential counts were made before phenylindandione administration. Following its administration, when the prothrombin concentration reached a level of 33 per cent, the procedures were repeated at the same hour of the day and under the same conditions as those existing when the initial values were determined. No significant alterations of the values could be detected. CONCLUSIONS In this preliminary report with observations made on 53 patients, it appears that the new anticoagulant, phenylindandione, if used cautiously could meet the need of clinicians for an anticoagulant intermediate in action between heparin and dicumarol, resembling dicumarol more closely than heparin in its behavior. An initial dose of 200 mg. is adequate. Fifty mg. the first day followed by 100 mg. the second day are inadequate. The average daily maintenance dose in 53 patients was 65 milligrams. The speed of action of the drug varied. In 38 of the 53 patients to whom the drug was administered it took twenty-eight hours or less to reach levels of 25 to 30 per cent of activity. It took on an average of forty-eight hours for the prothrombin concentration to return to its original level. Bleeding episodes occurred in 2 patients. One patient, C. L., had, without our knowledge, been given 500 mg. of dicumarol prior to receiving 100 mg. of phenylindandione. The second patient, G. M., had received an initial dose of 150 mg. and had a nosebleed on the fourteenth day of treatment. No effect upon liver function could be detected by means of the series of tests that were used. The sedi-mentation rate, platelet count, and white blood cell differential count do not appear to be altered by the anticoagulant.
No dogmatic statements can be made, but it is hoped that this report will stimulate further interest in this new anticoagulant.
